Suchergebnisse - "Knapper, Steven"

PubPharm (5)

1

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Harrison, C. | Nangalia, J. | Boucher, R. | +30

2

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide

enthalten in: Blood | 2017

von Harrison, C. | Mead, A. | Panchal, A. | +18

CommentIn: Blood. 2017 Oct 26;130(17):1873-1874. - PMID 29074591

3

Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis : results of the UK ROBUST Trial

enthalten in: British journal of haematology | 2015

von Mead, A. | Milojkovic, D. | Knapper, S. | +9

4

Response to ruxolitinib in patients with intermediate‐1–, intermediate‐2–, and high‐risk myelofibrosis: results of the UK ROBUST Trial

enthalten in: British journal of haematology | 2015

von Mead, A. | Milojkovic, D. | Knapper, S. | +9

5

Use of JAK inhibitors in the management of myelofibrosis : a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012

enthalten in: British journal of haematology | 2014

von Reilly, J. | McMullin, M. | Beer, P. | +11

1
[1]